Giant prolactinoma and effectiveness of medical management

Endocrine Practice

Volumn 16, Issue 1, 2010, Pages 42-46

  Acharya, Shrikrishna V ^a   Gopal, Raju A ^a   Menon, Padma S ^a   Bandgar, Tushar R ^a   Shah, Nalini S ^a  

^a KEM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BROMOCRIPTINE; CABERGOLINE; PROLACTIN; TESTOSTERONE;

ADOLESCENT; ADULT; ARTICLE; CANCER INVASION; CEREBROSPINAL FLUID RHINORRHEA; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GALACTORRHEA; GIANT PROLACTINOMA; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; MALE; MEDICAL CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCRIPTION; PROLACTIN BLOOD LEVEL; PROLACTINOMA; TESTOSTERONE BLOOD LEVEL; TONIC CLONIC SEIZURE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; VISUAL DISORDER; VISUAL FIELD DEFECT; VISUAL SYSTEM EXAMINATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ERGOLINES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROLACTIN; PROLACTINOMA; YOUNG ADULT;

EID: 77649122728     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09221.OR     Document Type: Article

References (23)

1. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet. 1998;352:1455-1461.
2. Shrivastava RK, Arginteanu MS, King WA, Post KD. Giant prolactinomas: Clinical management and long-term follow up. J Neurosurg. 2002;97:299-306.
3. Corsello SM, Ubertini G, Altomare M, et al. Giant prolactinomas in men: Efficacy of cabergoline treatment. Clin Endocrinol (Oxf). 2003;58;662-670.
4. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab.1985;60:698-705.
5. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992;13:220-240.
6. Kleinberg DL, Boyd AE 3rd, Wardlaw S, et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med. 1983;309:704-709.
7. Vance ML, Lipper M, Klibanski A, Biller BM, Samaan NA, Molitch ME. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist. Ann Intern Med.1990;112:668-673.
8. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331:904-909.
9. Biller BM, Molitch ME, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 1996;81:2338-2343.
10. Colao A, Di Sarno A, Landi ML, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997;82:3574-3579.
11. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518-2522.
12. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485-534.
13. Molitch ME. Dopamine resistance of prolactinomas. Pituitary. 2003;6:19-27.
14. Davis JR, Sheppard MC, Heath DA. Giant invasive prolactinoma: A case report and review of nine further cases. Q J Med. 1990;74:227-238.
15. Symon L, Jakubowski J, Kendall B. Surgical treatment of giant pituitary adenomas. J Neurol Neurosurg Psychiatry. 1979;42:973-982.
16. Pia HW, Grote E, Hildebrandt G. Giant pituitary adenomas. Neurosurg Rev. 1985;8:207-220.
17. Saeki N, Nakamura M, Sunami K, Yamaura A. Surgical indication after bromocriptine therapy on giant prolactinomas: Effects and limitations of the medical treatment. Endocr J. 1998;45:529-537.
18. Minniti G, Jaffrain-Rea ML, Santoro A, et al. Giant prolactinomas presenting as skull base tumors. Surg Neurol. 2002;57:99-103.
19. Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: Study of 12 men. Eur J Endocrinol. 2007;156:225-231.
20. Caccavelli L, Cussac D, Pellegrini I, Audinot V, Jaqut P, Enjalbert A. D2 dopaminergic receptors: Normal and abnormal transduction mechanisms. Horm Res. 1992;38:78-83.
21. Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR, MacFarlane IA. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf). 2002;52:43-49.
22. Odin P, Oehlwein C, Storch A, et al. Efficacy and safety of high-dose cabergoline in Parkinson's disease. Acta Neurol Scand. 2006;113:18-24.
23. Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008;93:3777-3784.